Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Delayed Xetra Other stock markets 11:40:23 2024-04-30 am EDT			5-day change	1st Jan Change
27.35 ^EUR	-0.87%		+0.13%	-18.67%

Apr. 30	Bayer: strategic collaboration with Evotec	CF
Apr. 30	Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	MT

BAYER AG : Berenberg maintains a Buy rating

August 06, 2021 at 04:41 am EDT

In a research note, Berenberg analyst Sebastian Bray has maintained his recommendation on the stock with a Buy rating. The target price is decreased from EUR 74 to EUR 60.

Latest news about Bayer AG

Bayer: strategic collaboration with Evotec	Apr. 30	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	Apr. 30	MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases	Apr. 30	MT
Bayer and Evotec Collaborate to Advance Precision Cardiology	Apr. 30	CI
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Bayer: positive results with Eylea in ophthalmology	Apr. 29	CF
Roche Holding AG: slimming down	Apr. 29
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
Bayer CEO wins first AGM shareholder vote	Apr. 26	RE
BAYER SAYS INVESTORS WITH 91.69% OF EQUITY CAPITAL REPRESENTED A…	Apr. 26	RE
Dpa-AFX Overview: COMPANIES from 26.04.2024 - 15:15	Apr. 26	DP
Bayer: CEO's positive AGM speech welcomed	Apr. 26	CF
Bayer investor Deka takes a stand against CEO in annual vote	Apr. 26	RE
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Human rights activists complain to OECD about Bayer over glyphosate	Apr. 25	DP
German cabinet approves restricted use of herbicide glyphosate	Apr. 24	RE
Dehoga: Challenging situation for company canteens	Apr. 23	DP
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Bayer: licensing agreement for biological insecticide	Apr. 23	CF
BAYER AG : Deutsche Bank reiterates its Neutral rating	Apr. 23	ZD
Bayer, AlphaBio Control Sign Exclusive License Deal for Biological Insecticide	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
JPMorgan rates Bayer at 'Neutral' - Target 34 euros	Apr. 22	DP
BAYER AG : JP Morgan remains Neutral	Apr. 22	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another peer group tidy up

April 14, 2024 at 03:26 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.35 EUR

Average target price

36.9 EUR

Spread / Average Target

+34.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-18.67%	28.73B
ELI LILLY AND COMPANY	+34.00%	704B
NOVO NORDISK A/S	+26.16%	577B
JOHNSON & JOHNSON	-7.75%	348B
MERCK & CO., INC.	+18.53%	327B
ABBVIE INC.	+4.95%	288B
ASTRAZENECA PLC	+15.25%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.89%	147B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Berenberg maintains a Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals